Patents by Inventor Markus Eser

Markus Eser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE
    Publication number: 20220048994
    Abstract: The invention relates to a trispecific antigen-binding molecule, wherein the antigen-binding molecule is at least tetravalent and comprises an antigen-binding site having specificity against a first antigen epitope, an antigen-binding site having specificity against a second antigen epitope and two antigen-binding sites having specificity against a third antigen epitope and its use a medicament for tumor therapy.
    Type: Application
    Filed: November 3, 2021
    Publication date: February 17, 2022
    Inventors: Melvyn Little, Eugene Zhukovsky, Markus Eser, Michael Weichel, Thorsten Gantke, Uwe Reusch, Kristina Ellwanger, Fabrice Le Gall
  • CD3 binding domains
    Patent number: 10066015
    Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 4, 2018
    Assignee: Affirmed GmbH
    Inventors: Eugene Zhukovsky, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala McAleese-Eser
  • ANTIMICROBIAL AGENTS AND SCREENING METHODS
    Publication number: 20170173008
    Abstract: Disclosed herein are antibacterial and antimicrobial compositions and methods of use. Also disclosed are screening assays for identification of an agent that specifically inhibits DsbB or bVKOR. Such methods are useful, for example, in identifying antibacterial and antimicrobial agents and compositions.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Beckwith Roger JONATHAN, Rachel DUTTON, Markus ESER, Cristina LANDETA, Jessica L. BLAZYK, Brian M. MEEHAN, Feras HATAHET, Dana BOYD
  • TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE
    Publication number: 20170037128
    Abstract: The invention relates to a trispecific antigen-binding molecule, wherein the antigen-binding molecule is at least tetravalent and comprises an antigen-binding site having specificity against a first antigen epitope, an antigen-binding site having specificity against a second antigen epitope and two antigen-binding sites having specificity against a third antigen epitope and its use a medicament for tumor therapy.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Inventors: Melvyn LITTLE, Eugene ZHUKOVSKY, Markus ESER, Michael WEICHEL, Thorsten GANTKE, Uwe REUSCH, Kristina ELLWANGER, Fabrice LE GALL
  • CD3 BINDING DOMAINS
    Publication number: 20160039934
    Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.
    Type: Application
    Filed: August 6, 2015
    Publication date: February 11, 2016
    Inventors: Eugene ZHUKOVSKY, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala Mcaleese-Eser